August 15, 2016

Lung Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email

The HARMONIC™ Study: PHase II Trial of LP-300 in Combination with CArboplatin and PemetRexed in Never SMOker Patients with Relapsed AdvaNced PrImary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Zhejiang Teruisi Pharma TRS00303001: A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety between TRS003 and China-approved Bevacizumab Administered in Combination with Paclitaxel-Carboplatin in Subjects with Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) 

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression

A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Relapsed/Refractory Small Cell Lung Cancer

A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Nonsmall Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer

A Phase 2 Study of BA3011 Alone and in Combination with NIVOLUMAB in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) who had prior disease progression on a PD-1/L-1 Inhibitor

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Return to Clinical Trials at GCC